KYTHERA Biopharmaceuticals hopes to one day help patients want to take (its product) on the chin. A maker of pharmaceutical products for the aesthetics market, KYTHERA is developing an injectable drug used to reduce submental fat, which can cause what is colloquially known as a "double chin." The company is seeking to commercialize the drug, currently in clinical stage development, in the US and Canada. It also has trials underway in Europe through a licensing agreement with Bayer. Formed in 2004, the company filed to go public in mid-2012. KYTHERA intends to use a significant portion of the proceeds raised in its IPO (up to $86.2 million) to fund advanced-stage clinical trials for its drug.